Skip to main content

Mitral Valve Regurgitation of Any Grade

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Philips
PhilipsNetherlands - Amsterdam
1 program
TransEsophageal Echocardiography and TransEsophageal EchocardiographyN/A1 trial
Active Trials
NCT03286088Completed120Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PhilipsTransEsophageal Echocardiography and TransEsophageal Echocardiography

Clinical Trials (1)

Total enrollment: 120 patients across 1 trials

NCT03286088PhilipsTransEsophageal Echocardiography and TransEsophageal Echocardiography

Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection

Start: Aug 2017Est. completion: Dec 2019120 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.